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Abstract
The question of whether the distinct isoforms of the family of enzymes phosphoinositide 3-kinases (PI3Ks) play redundant
roles within a cell or whether they control distinct cellular processes or distinct steps within the same cellular process has
gained considerable importance in the recent years due to the development of inhibitors able to selectively target
individual isoforms. It is important to understand whether inhibition of one PI3K can result in compensatory effect from
other isoform(s) and therefore whether strategies aimed at simultaneously blocking more than one PI3K may be needed. In
this study we investigated the relative contribution of distinct PI3K isoforms to endothelial cells (EC) functions specifically
regulated by the sphingolipid sphingosine-1-phosphate (S1P) and by high density lipoproteins (HDL), the major carrier of
S1P in human plasma. Here we show that a co-ordinated action of different PI3Ks is required to tightly regulate remodelling
of EC on Matrigel, a process dependent on cell proliferation, apoptosis and migration. The contribution of each isoform to
this process appears to be distinct, with the class II enzyme PI3K-C2b and the class IB isoform p110c mainly regulating the
S1P- and HDL-dependent EC migration and PI3K-C2a primarily controlling EC survival. Data further indicate that PI3K-C2b
and p110c control distinct steps involved in cell migration supporting the hypothesis that different PI3Ks regulate distinct
cellular processes.
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Introduction
Since the identification of a phosphoinositide 3-kinase (PI3K)
activity, several intracellular functions have been demonstrated to
be dependent on this enzyme. Eight isoforms of PI3K exist in
mammals, grouped into three classes according to their structure
and substrate specificity [1,2]. Class I PI3Ks, further divided into
the subgroups IA and IB, are dimers composed of a catalytic and
regulatory subunit. Class IA comprises the catalytic subunits
p110a,b and d whereas the only catalytic subunit of class IB PI3K
is p110c. Class I PI3Ks are mostly responsible for synthesis of the
well established second messenger phosphatidylinositol 3,4,5-
trisphosphate [PtdIns(3,4,5)P3] in vivo. Class II PI3Ks are mono-
mers of high molecular weight [1,2]. Three members exist, PI3K-
C2a, b and c and we demonstrated that they mainly catalyse the
synthesis of phosphatidylinositol 3-phosphate (PtdIns3P) in vivo
upon cellular stimulation [1,3–6]. More recently PtdIns3P has
been confirmed as the main specific product of PI3K-C2a by
using MEFs upon induction of PI3K-C2a knockout [7]. Finally,
the only class III PI3K isoform, hVps34, is mostly considered
responsible for the synthesis of a constitutive pool of PtdIns3P.
The identification of different PI3K isoforms led to questioning
whether these isoforms are redundant or rather they play distinct
and not overlapping roles in cell signalling [1]. This question has
become increasingly important, in particular with the develop-
ment of isoform-specific PI3K inhibitors that require a clear
understanding of distinct PI3K contribution in cellular biology and
disease for the evaluation of their safety and efficacy and their
pharmacological potential. Therefore it has become critical to
define which isoform is important for regulation of which cellular
function and to what extent [2]. Examples of co-operative action
of distinct PI3Ks have been reported, further supporting the
hypothesis that they do not play redundant functions [1,9]. Among
the eight PI3K isoforms, members of the class II subgroup remain
the least investigated and there is still a lot that needs to be
understood about the role of these isoforms [1,6]. Since class II
PI3Ks generate a different lipid product compared to class I [1,3–
7], it is likely that their roles are not overlapping with class I PI3Ks
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and therefore they may regulate distinct biological functions or
may co-operate with class I PI3Ks in regulating some processes
[1,8,9].
Sphingosine 1-phosphate (S1P) is generated by phosphorylation
of sphingosine produced by the enzymatic hydrolysis of ceramide,
a key intermediate in the synthesis of complex glycosylated
sphingolipids, that can either be generated de novo or by breakdown
of sphingomyelin through the activities of sphingomyelinase [10].
S1P levels in mammalian cells are regulated by the action of two
sphingosine kinases, two phosphatases and a lyase [10]. Data have
revealed that S1P can either act as a second messenger inside the
cells or it can be secreted and it can bind specific G-protein
coupled receptors (GPCR), the S1P receptors 1–5 [11]. Several
cells are able to release S1P, although the major sources are
platelets, erythrocytes and endothelial cells (EC). A gradient of S1P
exists, with low levels in tissues and high levels in serum and
plasma, where concentration of S1P is estimated to be around 400
and 200 nM respectively [12]. In plasma, S1P is found associated
with albumin and lipoproteins, including low density lipoproteins,
very low density lipoproteins and high density lipoproteins (HDL)
[13]. The majority of the lipoprotein-bound S1P (,54%) is
associated with HDL, mostly concentrated in small dense
subfraction HDL3, that show higher S1P/sphingomyelin ratio
compared to large HDL2 [14]. S1P has a critical role in vascular
development, in endothelial functions and regulation of angio-
genesis in adults [15,16]. Indeed, deletion of the S1P receptor 1
(EDG-1/S1P1) in mice is embryonic lethal because of massive
haemorrhaging due to defect in vasculature stabilisation [17]. EC-
specific deletion mimics the effect of the total knock out, indicating
that S1P1 signalling in EC is critical for regulation of vascular
maturation [18]. In addition, S1P has a key role in angiogenesis in
adults and is able to stimulate EC proliferation, shape change and
migration [19]. Furthermore there is growing evidence that S1P
may account for many of the cardiovascular effects of HDL
including the ability to promote vasodilation, EC migration and
angiogenesis [20]. Specifically, S1P is one of the most potent
inducers of chemotaxis in EC in vitro and of differentiation into
capillary-like structures on Matrigel [21].
Data have indicated a key role for class I PI3K in S1P-
dependent EC migration and it has been shown that at least two
class I isoforms, the class IA p110b and the class IB p110c, are
involved in S1P-mediated cell migration in EC [22]. Not
surprisingly, these are the isoforms able to be activated
downstream of GPCR [2]. We recently demonstrated that at least
some members of the class II subgroup of PI3Ks can also be
activated downstream of GPCR activation. Specifically we showed
that lysophosphatidic acid (LPA) can activate PI3K-C2b to
regulate migration of cancer cells [5]. These data, together with
results showing that the S1P-induced migration is partially
resistant to treatment with the classical PI3K inhibitor wortman-
nin [22], a feature of at least some of the class II PI3K isoforms
[1,5,6,23], prompted us to investigate the potential involvement of
class II PI3Ks on EC migration and capillary morphogenesis
induced by S1P and HDL.
Here we show that downregulation of class II PI3Ks expression
inhibits EC differentiation and morphogenesis. Detailed analysis of
the specific role of these enzymes reveals that PI3K-C2b mainly
regulates EC migration induced by treatment with either S1P or
HDL3 whereas PI3K-C2a is involved in EC survival. Downreg-
ulation of p110c also affects EC migration and our data indicate
that PI3K-C2b and p110c may have distinct, non overlapping role
in regulation of this process. Taken together these data suggest a
co-operative action of distinct PI3K isoforms to regulate EC
morphogenesis.
Materials and Methods
Materials
Anti PI3K-C2a and anti PI3K-C2b were from BD Transduc-
tion LaboratoriesTM (BD Biosciences, Oxford, UK), anti Akt, anti
ERK2, and anti actin from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), anti phospho Ser473 Akt, anti-phospho ERK1/
2, anti S6 and anti- p110c from Cell Signaling Technology
(Danvers, MA, USA). Wortmannin, LY294002 and S1P were
from Sigma Adlrich (St.Louis, MO, USA). AS252424 and
AS605240 were from Alexis (EnzoH Life Sciences, Vinci, Italy).
A66 was kindly provided by Prof Peter Shepherd (University of
Auckland, New Zealand).
Cell Culture and Downregulation of PI3K Isoforms Using
siRNA
HUVEC were purchased from TCS CellWorks (Buckingham,
UK) and grown in EGMTM BulletkitTM or EGMTM-2
BulletkitTM (Lonza, Basel, Switzerland) supplemented with
10% FBS. siRNA duplexes used in this study were based on
the human cDNA sequences encoding PI3K-C2a, PI3K-C2b
and p110c. Specific siRNAs targeting the class II isoforms
PI3K-C2a (Sequence 1: 59-AAGTCCAGTCACAGCGCAAAG-
39; Sequence 2: 59-AAGTACAGAATGAGGAGATGG-39) and
PI3K-C2b (Sequence 1: 59-AAGAATGCGACGCCTGG-
CAAG-39) were custom-made by Qiagen (Qiagen, Milan, Italy).
ON-TARGETplus SMARTpool siRNA (Sequence 1) and ON-
TARGETplus single sequence (Sequence 2) targeting p110c
together with ON-TARGETplus single sequence targeting
PI3K-C2b (Sequence 2) were from Dharmacon (Thermo Fisher
Scientific, Inc., Waltham, MA, USA). Negative silencer non
targeting siRNA (‘‘scrambled’’) was from AmbionH (Life
Technologies Ltd, Paisley, UK). Transient transfections were
performed using OligofectAMINETM (Life Technologies Ltd,
Paisley, UK) following the manufacturer instructions and
efficiency of downregulation was evaluated by quantitative Real
Time PCR and Western blotting.
Lipoprotein Isolation
HDL subfraction 3 (HDL3 density 1.125–1.21 g/ml) was
obtained from freshly isolated human plasma by preparative
ultracentrifugation, dialysed versus PBS containing 0.01% EDTA
and sterilised by filtration. Protein content was determined using
the colorimetric Bradford assay. The Institutional Ethic Commit-
tee approved the study and informed written consent was obtained
from all participating subjects. The study was conducted according
to the standards of the Declaration of Helsinki and Good Clinical
Practise.
Real-time Quantitative (RT)-PCR
Total RNA was extracted and reverse transcribed as described
[24]. Three ml of cDNA was amplified by real-time quantitative
PCR with 1X SYBER Green universal PCR mastermix (Bio-Rad).
The specificity of the Syber Green fluorescence was tested by
plotting fluorescence as a function of temperature to generate a
melting curve of the amplicon. The primers used are listed in the
Table S1. Each sample was analysed in duplicate using the IQTM-
Cycler (Bio-Rad, Hemel Hempstead, UK).
Migration Assay
Cell migration was performed in Transwell chambers (tissue
culture treated, 10 mm diameter, 8 mm pores, Nunc, Rochester,
NY or 6.5 mm diameter, 8 mm pores, CostarH, Corning
Class II PI3Ks in Endothelial Cells
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Incorporated, Corning, NY) coated with 100 mg/ml gelatin
(0.1% in acetic acid). HUVECs were serum starved overnight in
M199 containing 0.5% FBS, pre-treated with the indicated
inhibitors for 30 minutes and detached. Cells were resuspended
in M199 containing 0.5% bovine serum albumin and the
specific inhibitor (or vehicle control) and added to the top of
each migration chamber. Cells were then allowed to migrate in
the presence of 1 mM S1P or 200 mg/ml HDL3 in the lower
chamber. Where necessary, each inhibitor was also added in the
lower chamber therefore migration was performed in the
continuous presence of the inhibitor to be tested. After 4 hours,
cells that had not migrated were gently removed by using a
cotton swab, whereas migrated cells were fixed with 4%
paraformaldehyde, stained with 1% crystal violet and counted
using a phase-contrast microscopy. Alternatively, 24 h after
transfection with the indicated siRNAs, cells were serum starved
overnight in M199 containing 0.5% FBS, then resuspended in
M199 containing 0.5% bovine serum albumin and plated on
Transwell as above.
Random Motility Assay
Migration of HUVEC cells was assessed by time-lapse video
microscopy. Briefly, 48 hours after transfection, 256103 cells
were seeded in duplicates on 12-well plates. After incubation for
4 h cells were transferred to an inverted phase contrast
microscope (Zeiss Welwyn Garden City, UK) with an environ-
mental chamber maintaining a 37uC, 5% CO2 atmosphere.
Sequential images were collected using a 106 phase contrast
objective at intervals of 6 min for a total period of 9 hours.
Analysis of motility was determined by measuring the velocity of
at least 15 cells/field using the MetaMorphH Software version
7.7 (Downington, PA, USA). Each experiment was performed in
duplicate.
Angiogenesis in vitro
Growth factor-reduced MatrigelTM (BD Biosciences, Oxford,
UK) was allowed to polymerise in a 96 well plate for 2 hours at
37uC. Untransfected or transfected HUVECs were serum starved
in M199 containing 0.5% FBS overnight. Cells were then
detached and plated (103) and 1 mM S1P or 200 mg/ml HDL3
were added to the cells where necessary. Alternatively serum
starved HUVEC were plated on Matrigel in the presence or
absence of 1 mM A66 and the appropriate stimuli. Each
experimental condition was performed in triplicate. EC migration
and rearrangement was visualised after 4 to 6 hours using an
Axiovert200 microscope (106 objective) and the number of
branching points counted in five fields covering the whole matrigel
surface. Only points generating at least three tubules were
counted. Representative fields were photographed using an 106
objective on an Axiovert200 microscope (Zeiss Welwyn Garden
City, UK).
Western Blotting Analysis
Cells were lysed in a buffer containing 1% Triton X-100
supplemented with protease inhibitors and phosphatase inhib-
itors cocktails (Sigma Adlrich, St.Louis, MO, USA). Protein
content was determined using the colorimetric Bradford assay.
Proteins were then separated by SDS-PAGE and transferred
onto a nitrocellulose membrane. Membrane were saturated at
room temperature in PBS containing 5% non fat milk for 1 h
at room temperature, washed with PBS containing 0.1%
Tween-20, then incubated overnight at 4˚C with the primary
antibody followed by incubation with peroxidase conjugated
anti-mouse or anti rabbit IgG (Sigma Aldrich, St.Louis, MO,
USA) for one hour at room temperature. Immunocomplexes
were detected by enhanced chemiluminescence (Amersham
ECL Plus, GE Healthcare UK Ltd, Little Chalfont, UK). For
densitometry analysis, levels of phosphoSer473 Akt and
phosphoERK were normalised to levels of actin. Alternatively,
membranes were stripped and incubated with total Akt or total
ERK and levels of phosphorylated proteins were normalised to
total protein levels. Values were then expressed as fold increase
over values obtained in cells transfected with scrambled siRNA
and unstimulated.
Caspase-3 Assay
Assay was performed in duplicates following the manufacturer’s
instructions (EnzChekH Caspase-3 Assay Kit #2, Molecular
ProbesH, Life Technologies Ltd, Paisley, UK). Briefly, cells were
harvested 48 h after transfection, washed in PBS and then lysed on
ice for 30 min. Lysates were centrifuged and transferred to
individual micro plates (background fluorescence was determined
using lysis buffer). An equal volume of 26 substrate working
solution was added to each sample and control, and the plates
were incubated in dark at room temperature for approximately 30
minutes. Fluorescence was measured using a microplate fluorom-
eter (FluoStar Optima, BMG LABTECH, GmbH). Fluorescence
units were normalised by the total protein content.
Annexin V Staining
HUVEC were harvested 48 hours after transfection and stained
with FITC Annexin V apoptosis detection kit I (BD Biosciences,
Oxford, UK) according to manufacturer instructions. Cells
positive for Annexin V and negative for propidium iodide were
gated. Cells were analysed by flow cytometry using a FACScalibur
flow cytometer (BD Biosciences, Oxford, UK) and cellQuest
software for data analysis.
MTT Assay
Assay was performed as previously described [25]. Briefly,
24 h post-transfection HUVEC were incubated in serum free
media for further 24 h. Alternatively, HUVEC were incubated
for 24 h in serum free with or without 1 mM S1P or in the
presence of serum as control. 3-(4,5-Dimethyldiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (Sigma Adlrich, St.Louis, MO,
USA) solution in M199 (500 mg/ml final concentration) was
added to each well for the last 5 h. After washing, DMSO was
added to the wells for 15 min, collected and absorbance at
570 nm was determined by using a microplate reader.
Metabolic Labelling and HPLC Analysis of PtdIns3P Levels
HUVEC were labelled with 5 mCi/well of [3H]myo-inositol
(PerkinElmer, Waltham, MA, USA) in inositol free-media M199
containing 0.5% FBS for 24 h. After one wash in PBS, cells were
incubated for 15 min in serum free M199 before stimulation with
1 mM S1P for the indicated times. Cells were then lysed with 1 M
HCl supplemented with 1 mM TTBSA and phosphoinositides
were extracted, deacylated and analysed by HPLC, as previously
described [4].
Statistical Analysis
Data are expressed as means 6 SEM. Unless otherwise stated,
differences between groups were analysed by Student’s t test in
Excel (paired, one-tailed distribution) and p,0.05 was considered
statistically significant.
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Results
Different PI3K Isoforms are Involved in Regulation of EC
Migration Induced by S1P and HDL3
It has been reported that S1P is able to stimulate migration of
HUVEC in a mechanism involving different class I PI3K isoforms
[22]. The authors however showed that there is also a component
of cell migration that is not inhibited by the classical PI3K
inhibitor wortmannin. Since class II PI3Ks are more resistant to
classical PI3K inhibitors [1,5,6,23] and they have been involved in
migration induced by lysophospholipids [1,5,6], we decided to
investigate whether these PI3K isoforms might also be required for
the S1P-induced cell migration.
Cells were pre-treated with generic or isoform-specific PI3K
inhibitors and migration was determined by Transwell assays in
the continuous presence of the inhibitors. Consistent with
published data, these experiments revealed that treatment with
100 nM wortmannin only partially inhibited the S1P-induced
migration of HUVEC (Figure 1A). Similarly, a partial inhibition of
migration was detected upon treatment with 25 mM of the
reversible PI3K inhibitor LY294002 (Figure 1B). A detailed
analysis of the effect of LY294002 on this process revealed that
treatment with up to 5 mM did not affect migration (Figure S1A,B)
whereas a slight inhibition was detected upon treatment with
10 mM LY294002 (Figure S1C). None of these treatments affected
the basal migration (Figure 1A,B, Figure S1A–C). These results
indicated that the S1P-dependent migration was only partially
reduced by classical, generic PI3K inhibitors.
It has been previously reported that the class I PI3K isoforms
p110b and p110c are specifically involved in the S1P-induced
migration of HUVEC [22]. To assess the role of these isoforms in
our experimental conditions HUVEC were first treated with
inhibitors that mainly target the class I PI3K isoform p110c. A
partial, but significant inhibition of the S1P-induced migration was
detected in cells upon treatment with the compounds AS252424
(Figure 1C) and AS605240 (Figure S1D). Interestingly, in contrast
with reported data, in these experimental conditions, no inhibition
of cell migration was detected when cells were treated with the
specific p110b inhibitor TGX221 (Figure S1E). As for wortmannin
and LY294002, none of these treatments affected the basal
migration (Figure 1C, Figure S1D,E). The partial inhibitory effect
of AS252424 and AS605240 on S1P-induced migration is
consistent with the partial inhibition observed using wortmannin
and LY294402 and indicates that p110c is required for S1P-
induced cell migration but it is not the only enzyme involved in
regulation of this process. This conclusion supports the hypothesis
that PI3Ks more resistant to generic inhibitors may be also
involved in this process.
Since S1P is a key component of HDL, we then investigated the
effect of PI3K inhibitors on HDL3-induced cell migration.
Consistent with data obtained with S1P alone, no increase in
migration was detected in cells upon treatment with wortmannin
(Figure 1D) whereas 5 mM LY294002 did not affect this process
(Figure 1E) and treatment with AS252424 partially blocked the
HDL3-induced migration (Figure 1F).
Taken together these data indicate that S1P and HDL3 induce
HUVEC migration in a mechanism which is either partially
independent on PI3K or involves activation of PI3Ks more
resistant to treatment with the classical inhibitors.
Class II PI3K Isoforms are Involved in S1P- and HDL-
induced Cell Migration
As mentioned above, one of the features of class II isoforms
PI3K-C2a and PI3K-C2b compared to class I enzymes is their
peculiar resistance to treatment with classical PI3K inhibitors
[1,6]. In order to determine whether class II PI3Ks have a role
in regulation of S1P- and HDL3-dependent migration in
HUVEC, we decided to investigate the effect of downregulation
of their protein expression on these processes using specific
siRNAs. First we checked whether transfection of HUVEC
affected the S1P-induced cell migration by using a non-
targeting, ‘‘scrambled’’ siRNA as control. Transfection of
HUVEC reduced the number of migrated cells compared to
untransfected cells both in unstimulated and in stimulated
conditions (Figure S2A), as expected from cells treated with
transfection reagent. Nevertheless, transfected cells were still
able to respond to S1P stimulation in a manner which was
comparable to untransfected cells (Figure S2A) indicating that
the transfection procedure does not affect the ability of HUVEC
to migrate upon S1P stimulation. We then investigated the S1P-
dependent migration in HUVEC upon PI3K-C2a and PI3K-
C2b downregulation. Two distinct siRNAs were used to
downregulate the expression levels of each class II PI3K
isoform (Figure 2A, Figure S2B). Data revealed that downreg-
ulation of PI3K-C2b specifically reduced the S1P-mediated cell
migration (Figure 2B and Figure S2C). A reduction in cell
migration upon S1P stimulation was also detected in cells upon
downregulation of PI3K-C2a (Figure 2C and Figure S2D).
Interestingly, we observed a slight but significant inhibition of
S1P-induced migration in cells treated with 1 mM of the
compound A66 (Figure S2E). It has been reported that A66
is a specific inhibitor of the class IA PI3K isoform p110a (IC50
32 nM), able to reduce Akt phosphorylation in specific cancer
cells at concentrations in the nanomolar range [26]. The
observation that PI3K-C2b is the only other PI3K isoform to
be inhibited by this compound with an IC50 in the nanomolar
range (462 nM) [26] and that treatment of HUVEC with 1 mM
A66 does not inhibit the S1P-induced Akt phosphorylation
(described below) may suggest that the detected effect on cell
migration is due to at least a partial inhibition of PI3K-C2b.
Consistent with previously reported data [22] and with our
experiments using AS252424 and AS605240 (Figure 1C and
Figure S1D), downregulation of p110c using two distinct siRNAs
also inhibited the S1P-dependent cell migration (Figure 2D, Figure
S2F). Efficiency of p110c knock down was assessed by qPCR
analysis (Figure S3A,B). This analysis also confirmed that
downregulation of each PI3K did not affect the mRNA levels of
the others (Figure S3B-D). Taken together these data reveal that
class II PI3Ks and p110c are involved in EC migration induced by
S1P.
We then investigated whether these PI3K isoforms had also a
role in HDL3-induced cell migration. Data demonstrated that
knockdown of PI3K-C2b indeed inhibited cell migration upon
HDL3 stimulation (Figure 3A) whereas downregulation of PI3K-
C2a did not appear to affect this process (Figure 3B). Consistent
with data obtained with the inhibitors, knock down of p110c also
resulted in significant inhibition of HDL3-dependent migration
(Figure 3C).
Taken together these data indicate that class II PI3Ks (mainly
PI3K-C2b) and p110c regulate EC migration induced by both
S1P and HDL3.
Class II PI3K Isoforms Regulate EC Morphogenesis
Since migration is a crucial process in EC shape change and
morphogenic rearrangement on Matrigel we then analysed the
effect of downregulation of the PI3K isoforms on this process.
Images of unstimulated, S1P- and HDL3-stimulated HUVEC
from one representative experiment are shown in Figure 4A.
Class II PI3Ks in Endothelial Cells
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e53808
Downregulation of either PI3K-C2a or PI3K-C2b using two
distinct siRNAs reduced HUVEC morphogenesis upon stimu-
lation with S1P and HDL3 (Figure 4B, Figure S4A). Inhibition
on the basal remodelling of the cells (induced by interaction
with Matrigel and likely by factors released by the cells) was
also consistently detected in cells upon downregulation of PI3K-
C2a (Figure 4B, Figure S4A). Parallel experiments also
indicated a reduction in the number of branching points in
cells upon downregulation of p110c using two distinct siRNAs
following stimulation with either S1P or HDL3 but not under
basal conditions (Figure 4C, Figure S4B,C). In addition,
consistent with data obtained in migration experiments,
treatment of HUVEC with 1 mM A66 significantly inhibited
both the HDL3- and S1P-induced remodelling on Matrigel
(Figure S4D,E).
Taken together these data indicate that a concerted action of
distinct PI3K isoforms is required to regulate the complex process
of EC morphogenesis on extracellular matrix.
Figure 1. Effect of PI3K inhibitors on S1P- and HDL3-induced EC migration. Serum-starved HUVEC were pre-treated with 100 nM
wortmannin (A,D), 25 mM LY294002 (B), 5 mM LY294002 (E) or 1 mM AS252424 (C,F) for 30 min. Cell migration induced by S1P (A–C) or HDL3 (D-F) was
determined by Transwell assays. Briefly, cells resuspended in the presence or absence of the specific inhibitor (or vehicle control) were allowed to
migrate in the presence of 1 mM S1P or 200 mg/ml HDL3 in the lower chamber for 4 h. Where necessary, each inhibitor was also added in the lower
chamber therefore migration was performed in the continuous presence of the inhibitor to be tested. After 4 h, migrated cells were fixed with 4%
paraformaldehyde, stained with 1% crystal violet and counted using a phase-contrast microscopy. Data are expressed as percentage of control (cells
untreated and unstimulated) and are means 6 SEM from 12 (A), 6 (B), 7 (C), 4 (D), 3 (E) and 5 (F) independent experiments. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0053808.g001
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Different PI3K Isoforms Control Distinct, not Redundant
Processes Regulating EC pro-Angiogenic Phenotype
Our data so far indicate that three different PI3K isoforms
participate in EC morphogenesis. Remodelling of EC on Matrigel
is the result of several cellular functions, including migration,
proliferation and survival. We therefore decided to investigate in
more details the specific contribution of each enzyme to this
process. Our data have shown that p110c and PI3K-C2b are
mainly involved in both S1P- and HDL3-induced cell migration.
To gain further insight into the specific role of each isofom in
regulation of cell migration we performed random motility assays.
Specifically, we measured the mean velocity of cells in serum by
tracking individual HUVEC transfected with siRNAs targeting
each distinct PI3K or with the control scrambled siRNA.
Representative track paths are shown in Figure 5A. A significant
reduction of the mean velocity was detected in cells upon p110c
but not PI3K-C2b downregulation (Figure 5B), suggesting that the
two PI3Ks may control different steps of cell migration.
To further investigate the hypothesis that p110c and PI3K-C2b
contribute to cell migration by regulating distinct functions, we
decided to analyse the effect of combined downregulation of
p110c and PI3K-C2b on S1P-induced cell migration. Consistent
with data previously presented, knockdown of either PI3K-C2b or
p110c alone significantly inhibited the S1P-induced migration
(Figure 5C). Importantly migration was further inhibited when
PI3K-C2b and p110c were downregulated simultaneously,
indicating that blockade of PI3K-C2b and p110c together has a
more pronounced inhibitory effect on S1P-dependent cell
migration. These data support the hypothesis that p110c and
PI3K-C2b have distinct, non redundant roles in regulation of cell
migration.
Our data so far indicated that PI3K-C2a is also critical for EC
morphogenesis. We therefore sought to determine the specific role
of PI3K-C2a in this process. Since downregulation of PI3K-C2a
had a smaller effect compared to PI3K-C2b knockdown (in the
case of S1P) or no effect at all (in the case of HDL3) on migration
Figure 2. Class II PI3Ks are involved in S1P-dependent EC migration. (A) Expression levels of PI3K-C2a and PI3K-C2b in HUVEC transfected
with a scrambled siRNA or siRNAs (‘‘Sequences 1’’) specifically targeting the indicated enzymes. (B-D) Twenty four hours after transfection with the
indicated siRNAs cells were serum starved overnight and S1P-mediated cell migration was determined by Transwell assays as above. Data are
expressed as percentage of migration of cells transfected with scrambled siRNA and unstimulated (control) and are means 6 SEM from 17 (B), 11 (C)
and 6 (D) independent experiments. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0053808.g002
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assessed by Transwell assays, we investigated whether downreg-
ulation of PI3K-C2a affected other cellular function(s) required for
EC remodelling. It has been recently reported that PI3K-C2a
knockdown reduces viability [27] and augmented apoptosis of
HUVEC [7]. Consistent with this, we observed that downregu-
lation of PI3K-C2a using two distinct siRNAs induced apoptosis
in HUVEC in the presence of serum as assessed by caspase 3 assay
(Figure 6A, Figure S5A) and by Annexin V staining (Figure 6B)
whereas no effect was observed upon silencing of PI3K-C2b
(Figure 6, Figure S5A). Consistent with these data, downregulation
of PI3K-C2a but not PI3K-C2b reduced the viability of HUVEC
upon serum starvation (Figure S5B). Although results from caspase
assay seemed to suggest a small increase in apoptosis upon
downregulation of p110c, values did not reach statistical
significance (Figure 6A). Moreover no increase in the number of
Annexin V-positive cells was detected in cells lacking p110c
(Figure 6B). Importantly, these data indicate that downregulation
of PI3K-C2a induces apoptosis of HUVEC even in the presence
of serum (Figure 6). These data suggest that PI3K-C2a but not
PI3K-C2b or p110c primarily regulates HUVEC survival, further
supporting the hypothesis that the distinct PI3Ks can regulate EC
morphogenesis by controlling different processes.
Downregulation of Class II PI3Ks does not Prevent the
S1P- or HDL3-dependent Phosphorylation of Akt or ERK
It has been reported that Akt activation is important for EC
migration [21,25] and capillary tube formation [25]. Furthermore
it has been shown that inhibition of ERK activation is able to
partially inhibit S1P-induced EC migration [22]. We therefore
investigated whether class II PI3Ks have a role in S1P- or HDL3-
dependent activation of ERK and Akt. Downregulation of PI3K-
C2a with two distinct siRNAs did not affect the S1P-dependent
ERK and Akt phosphorylation at its residue Ser473 (Figure 7,
Figure S6A). Phosphorylation of both enzymes upon S1P
stimulation was also clearly detectable in cells lacking PI3K-C2b
(Figure 7, Figure S6B). Consistent with this, treatment of HUVEC
with 1 mM A66, a concentration previously shown to be able to
inhibit the S1P-induced cell migration (Figure S2E), did not inhibit
the S1P-induced Akt or ERK phosphorylation (Figure S6C).
Knockdown of either PI3K-C2a or PI3K-C2b did not affect the
HDL3-mediated ERK or Akt phosphorylation (Figure 7). No
inhibition of ERK phosphorylation was observed in cells
transfected with siRNA targeting p110c (Figure 7) as previously
reported [22] whereas downregulation of p110c slightly affected
the HDL3-dependent and possibly the S1P-dependent Akt
phosphorylation, although values from densitometry analysis did
not reach significance in this latter case (Figure 7). On the other
hand treatment with classical PI3K inhibitors wortmannin and
LY294002 and the p110b inhibitor TGX221 completely blocked
the S1P-induced Akt but not ERK phosphorylation (Figure S6D),
consistent with previous report [22]. Interestingly, in these
experimental conditions treatment with either AS252424 or
AS605240 was also able to inhibit Akt but not ERK phosphor-
ylation upon S1P stmulation (Figure S6E).
These data indicate that class II PI3Ks do not regulate the S1P-
and HDL3-dependent Akt and ERK activation further supporting
the conclusion that class I and class II PI3Ks can activate distinct
signalling pathways. Interestingly, HPLC analysis of phosphoino-
sitides extracted from [3H]myo-inositol-labelled HUVEC revealed
Figure 3. Class II PI3Ks are involved in HDL3-dependent EC
migration. Twenty four hours after transfection with the indicated
siRNAs cells were serum starved overnight and HDL3-mediated cell
migration was determined by Transwell assays as above. Data are
expressed as percentage of migration of cells transfected with
scrambled siRNA and unstimulated (control) and are means 6 SEM
from 4 (A), 5 (B) and 5 (C) independent experiments. *p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0053808.g003
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a very rapid and transient increase in the levels of PtdIns3P, the
main lipid product of class II PI3Ks, upon S1P stimulation (Figure
S7). Future studies will focus on the identification of the specific
downstream effectors of PtdIns3P.
Discussion
In this study we investigated the relative contribution of
different PI3K isoforms to EC functions specifically regulated by
the sphingolipid S1P and the lipoprotein HDL3. Previous work
had demonstrated that EC migration upon stimulation with S1P
requires both class I isoforms p110b and p110c [22]. While the
contribution of these two isoforms is necessary for this process to
occur, data also suggested the existence of other signalling
pathways involved in this process. Based on evidence provided
in the previous study [22] and confirmed by our own results
showing that the S1P-dependent EC migration is only partially
inhibited by treatment with wortmannin and LY294002 we
hypothesised that class II PI3Ks could also be involved in this
process. Indeed class II PI3Ks are more resistant to treatment with
these classical PI3K inhibitors compared to class I PI3Ks [1,6].
Furthermore we previously reported that the class II enzyme
PI3K-C2b can be activated by the lysophospholipid LPA [5].
Our results demonstrated that downregulation of class II PI3Ks
inhibits the S1P-induced EC migration. By using two distinct
siRNAs and two inhibitors that mainly target p110c we also
confirmed the involvement of p110c in this process, consistent
with previous report [22]. We further showed that PI3K-C2b and
p110c play also a role in migration induced by treatment with
HDL3. More important, our data clearly demonstrated that all
three PI3K isoforms PI3K-C2a, PI3K-C2b and p110c contribute
to EC morphogenesis since downregulation of each of these
enzymes strongly prevents EC shape change and remodelling on
Matrigel.
These data indicated that a concerted action of distinct PI3Ks is
necessary to tightly regulate EC morphogenesis and raised the
Figure 4. Class II and class IB PI3Ks regulate remodelling of HUVEC. HUVEC transfected with the indicated siRNAs were serum starved in
M199 containing 0.5% FBS overnight before being detached and plated on growth factor reduced Matrigel in the presence of 1 mM S1P or 200 mg/ml
HDL3. EC rearrangement was visualised after 4 to 6 h using an Axiovert200 microscope. (A) Representative images of branching points formation in
HUVEC transfected with the indicated siRNAs (Sequences 1) in the absence or presence of S1P or HDL3. (B,C) Results from quantitative analysis in
HUVEC transfected with the indicated siRNAs (Sequences 2) in the absence or presence of S1P or HDL3. Data indicate the total number of branching
points and are means 6 SEM from 4 (B) and 3 (C) independent experiments. *p,0.01; **p,0.001.
doi:10.1371/journal.pone.0053808.g004
Figure 5. PI3K-C2b and p110c play distinct role in regulation of S1P-dependent cell migration. Random motility of HUVEC transfected
with the indicated siRNAs was monitored as described in the Materials and Methods section. (A) Representative track paths throughout time of 6 cells
are shown (8 h). (B) Data indicate the mean velocity/min and are means 6 SEM from 3 independent experiments. **p,0.01 vs cells transfected with
scrambled siRNA. (C) Results from Transwell assays performed in HUVEC transfected with the indicated siRNAs. Data are expressed as percentage of
migration of cells transfected with scrambled siRNA and unstimulated (control) and are means 6 SEM from 3 independent experiments. *p,0.01.
Downregulation of PI3K-C2b and p110c was confirmed by Western blotting.
doi:10.1371/journal.pone.0053808.g005
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question of whether these isoforms play redundant roles or they
regulate distinct processes ultimately controlling EC remodelling.
A more detailed analysis revealed that downregulation of PI3K-
C2b and p110c specifically affects morphogenesis induced by
treatment with either S1P or HDL3 whereas downregulation of
PI3K-C2a appears to inhibit the basal as well as the stimulated cell
remodelling. Inhibition of basal as well as vascular endothelial
growth factor (VEGF)-A- and serum-induced remodelling was
recently reported in HUVEC upon PI3K-C2a but not PI3K-C2b
downregulation [7]. These results may suggest distinct mecha-
nisms of activation of the two class II isoforms with a potential
selective activation of PI3K-C2b downstream of GPCR activation.
This would be consistent with our previous data demonstrating
that PI3K-C2b but not PI3K-C2a is involved in LPA-dependent
migration of cancer cells [5] but further studies are required to
validate this hypothesis.
We then investigated the specific contribution of each PI3K
isoform to EC shape change and morphogenesis. The switch of
EC towards a pro-angiogenic phenotype is the result of several
intracellular events such as cell proliferation, survival and
migration. Our results support the hypothesis that the contribution
of PI3K-C2b and p110c to EC remodelling is mostly associated to
their role in regulation of cell migration induced by either S1P or
HDL3. Although both enzymes control HUVEC migration, their
specific roles seem not to be overlapping. Indeed inhibition of
p110c but not PI3K-C2b was able to slightly but significantly
affect cell speed assessed by random motility assays, suggesting that
PI3K-C2b and p110c may regulate EC migration by controlling
distinct steps in this process. Moreover we observed that
simultaneous downregulation of p110c and PI3K-C2b inhibits
the S1P-induced migration to a greater extent than downregula-
tion of each PI3K isoform alone further supporting the hypothesis
that the two enzymes have non redundant roles in regulation of
cell migration.
The contribution of PI3K-C2a to EC remodelling appears to be
mainly associated to its role in regulation of EC survival. Our data
showed that downregulation of this enzyme induces apoptosis in
HUVEC even in the presence of serum, suggesting that the
reduced morphogenetic response may be attributed to intrinsic
increased apoptosis in cells lacking PI3K-C2a. Interestingly we
observed that treatment of HUVEC with 1 mM S1P was not able
to induce survival of serum starved HUVEC (Figure S5C). This
observation, together with data showing that knockdown of PI3K-
C2a consistently reduced the basal as well as the stimulated EC
remodelling further supports the hypothesis that the detected
inhibition of EC remodelling is at least partially due to the intrinsic
reduced viability of the cells upon downregulation of PI3K-C2a.
Several studies have reported a role for PI3K-C2a in regulation of
cell viability and/or survival [1,9]. Relevant to our own study it
was previously reported that PI3K-C2a is critical for HUVEC
viability [27]. Furthermore it has been recently shown that
downregulation of this enzyme increases apoptosis of HUVEC
upon serum and growth factors deprivation or upon treatment
with staurosporine [7]. More important retinas from tamoxifen-
inducible EC-specific PI3K-C2a depleted mice showed a 5.5-fold
increase in apoptosis compared to control littermates [7].
Taken together results from this study support the hypothesis
that a concerted action of distinct PI3K isoforms is required to
regulate the complex process of EC remodelling. The precise
mechanisms by which the enzymes are able to control this process
are still not completely defined. It has been previously proposed
that p110c can control EC migration through regulation of Rac1
activation [22]. Interestingly Rac1 has also been identified as a
downstream effector of PI3K-C2b in regulation of cell migration
[28]. On the other hand the specific effect of PI3K-C2a
downregulation on the VEGF-A-dependent EC functions has
Figure 6. Effect of PI3Ks downregulation on EC apoptosis. (A)
Results from caspase 3 assay performed on lysates from HUVEC
obtained 48 h after transfection with the indicated siRNAs. Data are
means 6 SEM from 3–4 independent experiments. Student’s t-Test: un-
paired *p,0.05 vs cells transfected with PI3K-C2b siRNA. (B) HUVEC
were transfected with the indicated siRNAs. After 48 h the percentage
of apoptotic cells was determined by Annexin V staining. Annexin V
positive and propidium iodide negative cells were gated. Results are
expressed as means 6 SEM from 3 independent experiments. *p,0.05
vs scrambled siRNA treated cells.
doi:10.1371/journal.pone.0053808.g006
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Figure 7. Class II PI3Ks do not regulate Akt or ERK activation. HUVEC transfected with the indicated siRNAs were serum starved in M199
containing 0.5% FBS overnight before stimulation with HDL3 or S1P for 10 min. Akt and ERK phosphorylation was assessed by Western blotting.
Densitometry analysis shows means 6 SEM from 3–4 (Akt) and 4 (ERK) independent experiments.
doi:10.1371/journal.pone.0053808.g007
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been at least partially ascribed to a defect in RhoA activation [7].
It remains to be addressed whether Rac1 or RhoA are also
involved in the S1P- and HDL3-mediated EC remodelling.
One of the main mechanisms by which class I and class II
PI3Ks can activate distinct signalling pathways is through
generation of different lipid products. Indeed, while it is well
established that class I PI3Ks mainly catalyse the synthesis of
PtdIns(3,4,5)P3 increasing evidence supports the conclusion that
PtdIns3P is the main lipid product of class II PI3Ks [1,3,4,7,9].
Interestingly we demonstrated that LPA specifically increases the
levels of PtdIns3P in ovarian and cervical cancer cells in a
mechanism dependent on activation of PI3K-C2b [5]. A time
course analysis revealed a very rapid and transient increase in
PtdIns3P levels upon S1P stimulation of HUVEC (Figure S7).
Being a distinct phosphoinositide compared to the main product of
class I PI3Ks PtdIns(3,4,5)P3, it is very likely that PtdIns3P
activates distinct downstream effectors and therefore distinct
cellular pathways. In this respect it is noteworthy that we observed
that downregulation of class II PI3Ks did not affect the S1P- or the
HDL3-dependent activation of Akt, one of the main downstream
effectors of class I PI3Ks/PtdIns(3,4,5)P3 pathway. The question of
whether class II PI3Ks are able to activate Akt has been critical to
address the issue of potential redundancy between these enzymes
and class I PI3K isoforms [1,9]. Our data here firmly demonstrate
that neither PI3K-C2a nor PI3K-C2b mediates Akt activation
upon S1P and HDL3 stimulation. On the other hand treatment of
HUVEC with classical PI3K inhibitors or the p110b specific
inhibitor TGX221 was able to completely block the S1P-induced
Akt phosphorylation, consistent with previous data [22]. Interest-
ingly it has also been demonstrated that PI3K-C2a does not
regulate the VEGF-A-dependent Akt activation [7].
Taken together these data strongly support the conclusion that
class I and class II PI3Ks activate distinct intracellular pathways
and therefore they play non redundant intracellular roles. Studies
using animal models are also now providing evidence supporting
this conclusion. It is well established that class I PI3Ks play a key
role in EC functions [29]. Knock out mice for the class IA catalytic
subunit p110a die early during embryogenesis (E9.5) and knock-in
strategies highlighted a critical role for this isoform in vascular
development [30]. A very recent and elegant study has now
revealed that PI3K-C2a has also a pivotal role in angiogenesis and
vascular development [7]. Homozygous global PI3K-C2a-deleted
embryos die between E10.5-E11.5 because of defects in vascular
formation [7]. Endothelial specific ablation of PI3K-C2a also
resulted in embryonic lethality highlighting a critical and specific
role for endothelial PI3K-C2a in normal vascular formation and
development. This study demonstrated that PI3K-C2a has a
pivotal role in regulation of angiogenesis and vascular barrier
integrity and highlighted a non redundant role of this isofom in
mouse development [7]. Studies also revealed that capillarisation
and arteriogenesis following unilateral limb ischemia were reduced
in muscles from PI3Kc2/2 compared to wild type mice, resulting
in delayed blood flow recovery in knock out animals [31] further
supporting the evidence for involvement of different PI3Ks in EC
functions. As for PI3K-C2b a study reporting a knock out model
for this enzyme specifically focussed on investigation of a potential
role for PI3K-C2b in epidermal differentiation and no further
investigation of the potential effects on ECs was performed [32].
Finally, the physiological relevance of our study is reinforced by
analysis of EC functions induced by high density lipoproteins, the
most relevant carrier of S1P in plasma. Our data demonstrate that
class II PI3Ks are also involved in EC angiogenic response
induced by HDL3. Numerous epidemiological studies have shown
an inverse correlation between plasma HDL cholesterol level and
the risk of coronary artery disease [33,34]. The beneficial effect of
these particles is related to their ability to remove cholesterol from
peripheral tissues and to protect against the development of
endothelial dysfunction regulating a wide range of cellular
activities [35]. For instance HDL has been shown to promote
prostacyclin and nitric oxide synthesis [36,37], to inhibit
leukocytes adhesion and platelets aggregation and to stimulate
EC proliferation and migration, crucial to both neovascularisation
and to a successful response to vascular injury [38,39]. The precise
mechanisms and the HDL components underlying these ather-
oprotective effects are still under investigation but apolipoprotein
A-I, the predominant HDL apolipoprotein, and several lyso-
sphingolipids such as S1P, sphingosylphosphorylcholine and
lysosulfatide have been identified as possible candidates. In
particular S1P is specifically concentrated in the small dense
HDL3 particles [14] and several studies have shown that HDL-
induced EC migration and morphogenesis involves both the
scavenger receptor class B member 1 (SR-B1) and S1P receptors
EDG-1/S1P1 and EDG-3/S1P3 [39–41], suggesting that HDL
binds SR-B1 on the cell surface bringing lysophospholipids into
direct proximity to their EDG receptors and that S1P may account
for the biological activity of this class of lipoproteins [42].
Consistent with this, our data reveal that the ability of HDL3 to
induce HUVEC migration and branching points formation on
Matrigel involves a similar dependence from the three PI3Ks, as
for S1P alone.
In conclusion our study has provided novel evidence of a direct
involvement of class II PI3Ks in EC functions regulated by S1P
and HDL3 and it has further indicated that a concerted action of
PI3K isoforms playing distinct, non redundant roles is required to
modulate EC migration and morphogenesis.
Supporting Information
Figure S1 Effect of PI3K inhibitors on S1P- and HDL3-
induced EC migration. Serum-starved HUVEC were pre-
treated with 1 mM LY294002 (A), 5 mM LY294002 (B), 10 mM
LY294002 (C), 1 mM AS605240 (D) or 100 nM of the specific
p110b inhibitor TGX221 (D) for 30 min. Cell migration induced
by S1P was determined by Transwell assays. Data are expressed as
percentage of control (cells untreated and unstimulated) and are
means 6 SEM from 6 (A), 5 (B), 6 (C), and 3 (D) independent
experiments. *p,0.05, **p,0.001.
(TIF)
Figure S2 Class II and class IB PI3Ks are involved in
S1P-induced EC migration. (A) Results from Transwell assays
performed in control, untransfected HUVEC and HUVEC
transfected with a scrambled siRNA. Data are expressed as
percentage of control (cells untransfected and unstimulated) and
are means 6 SEM from 6 independent experiments. (B) Levels of
PI3K-C2a and PI3K-C2b in cells transfected with specific siRNAs
(sequences 2) were assessed by Western blotting. (C-D) Results
from Transwell assays performed in HUVEC transfected with the
indicated siRNAs. Data are expressed as percentage of each
control (cells transfected with each siRNA and unstimulated) and
are means 6 SEM from 5 (C) and 4 (D) independent
experiments.*p,0.05. (E) Results from Transwell assays per-
formed in HUVEC treated with 1 mM of the inhibitor A66. Data
are expressed as percentage of control (cells untreated and
unstimulated) and are means 6 SEM from 4 independent
experiments.*p,0.05. (F) Results from Transwell assays per-
formed in HUVEC transfected with a scrambled siRNA or siRNA
specifically targeting p110c (sequence 2). Data are expressed as
percentage of each control (cells transfected with each siRNA and
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unstimulated) and are means 6 SEM from 2 independent
experiments.
(TIF)
Figure S3 RT-qPCR analysis of PI3Ks levels. (A) Down-
regulation of p110c mRNA levels using two distinct siRNAs was
determined by RT-qPCR. (B) HUVEC were transfected with
siRNAs targeting the indicated PI3Ks. Efficiency and specificity of
downregulation was determined by RT-qPCR.
(TIF)
Figure S4 Class II and class IB PI3Ks are involved in
remodelling of HUVEC. (A-C) Results from analysis of EC
rearrangement. Data indicate the total number of branching
points and are means 6 SEM from 3–4 (A), 3 (B), and 4 (C)
independent experiments. (D,E) The S1P- and HDL3-dependent
HUVEC was assessed in the absence or presence of 1 mM A66.
Representative images (D) and data indicating the total number of
branching points (E) are shown. Data are means 6 SEM from 4
independent experiments. **p,0.01.
(TIF)
Figure S5 Effect of PI3Ks downregulation on EC
apoptosis. (A) Results from caspase 3 assay performed on lysates
from HUVEC obtained 48 h after transfection with the indicated
siRNAs (sequences 2). Data are means 6 SEM from 2
independent experiments. (B) HUVEC transfected with the
indicated siRNAs were incubated in serum free M119 after 24 h
from transfection. Viability of cells was assessed by MTT assay
after further 24 h. Data are expressed as fold increase over control
(cells transfected with scrambled siRNA) and are means 6 SEM
from 4–6 independent experiments. (C) Results from MTT assays
performed in HUVEC incubated in serum free M199 or M199
supplemented with 1 mM S1P or 10% FBS. Data are expressed as
fold increase over control (cells in serum free media) and are
means 6 SEM from 5 independent experiments.
(TIF)
Figure S6 Effect of PI3Ks downregulation and PI3K
inhibitors on the S1P-dependent Akt and ERK phos-
phorylation. Representative images of Western blotting analysis
of Akt and ERK phosphorylation performed in HUVEC.
Membranes were then stripped and incubated with the corre-
sponding total antibodies. (A-B) HUVEC transfected with the
indicated siRNAs were serum starved overnight before stimulation
with 1 mM S1P for 10 min. (C) Serum-starved HUVEC were
treated with the indicated concentration of A66 for 30 min before
stimulation with 1 mM S1P for 10 min in the presence of the
inhibitor. (D) Serum-starved HUVEC were treated with 100 nM
wortmannin, 10 mM LY294002 or 100 nM TGX221 for 30 min
before stimulation with 1 mM S1P for 10 min in the presence of
the inhibitors. (E) Serum-starved HUVEC were treated with 1 mM
AS252424 or AS605240 for 30 min before stimulation with 1 mM
S1P for 10 min in the presence of the inhibitor.
(TIF)
Figure S7 S1P induces de novo synthesis of PtdIns3P.
HUVEC were labelled with [3H]myo-inositol before stimulation
with 1 mM S1P for the indicated times. Phosphoinositides were
then extracted, deacylated and analysed by HPLC. Data show
levels of glyceroPtdIns3P normalised for the levels of glyceropho-
sphatidylinositol (gPtdIns) and expressed as percentage of
PtdIns3P/gPtdInsP in unstimulated cells (control). Data are means
6 SEM from 3 (time points 1 and 5 min) and 1 (time point
10 min) independent experiments.
(TIF)
Table S1 Primers used for RT-PCR analysis presented
in Figure S3.
(DOC)
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